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Introduction
The microtubule motor cytoplasmic dynein and its activator 
dynactin, which mediate minus end–directed movement, have 
important roles in both interphase and dividing cells. In inter-
phase cells, the dynein–dynactin complex is essential for ves-
icle and organelle transport, such as ER-to-Golgi vesicular 
traffi  cking (for review see Schroer, 2004). The dynein–dynactin 
motor complex also transports RNA particles (Carson et al., 
2001), aggresomes (Johnston et al., 2002), and virus particles 
along microtubules (Dohner et al., 2002). During cell divi-
sion, dynein and dynactin play a critical role in both nuclear 
envelope breakdown and spindle formation (for review see 
Schroer, 2004).
Consistent with these multiple cellular roles, dynein 
and dynactin function are required in higher eukaryotes. Loss 
of dynein or dynactin is lethal in Drosophila melanogaster
(Gepner et al., 1996), and mice homozygous for loss of cyto-
plasmic dynein heavy chain die early in embryogenesis 
(Harada et al., 1998). Cells cultured from dynein heavy 
chain–null embryos show fragmented Golgi and a disper-
sal of endosomes and lysosomes throughout the cytoplasm 
(Harada et al., 1998).
Neurons appear to be particularly susceptible to defects 
in dynein–dynactin complex function. The dominant-negative 
mutation in D. melanogaster Glued, which encodes a truncated 
form of the p150
Glued subunit of dynactin, shows defects that are 
most profound in neurons (Harte and Kankel, 1983). Two 
N-ethyl-N-nitrosurea–induced point mutations in cytoplasmic 
dynein heavy chain cause slowly progressive motor neuron dis-
ease in mice (Hafezparast et al., 2003). Legs at odd angles (Loa) 
and Cramping (Cra1) mice each carry missense mutations in a 
highly conserved domain of cytoplasmic dynein that mediates 
subunit interactions. When homozygous, these mutations are 
lethal; heterozygous mice exhibit progressive loss of motor 
neurons, leading to muscle weakness and atrophy (Hafezparast 
et al., 2003). A similar phenotype is observed in transgenic mice 
with a targeted disruption of dynactin in motor neurons 
(LaMonte et al., 2002).
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T
he microtubule motor cytoplasmic dynein and its ac-
tivator dynactin drive vesicular transport and mitotic 
spindle organization. Dynactin is ubiquitously ex-
pressed in eukaryotes, but a G59S mutation in the 
p150
Glued subunit of dynactin results in the speciﬁ  c degen-
eration of motor neurons. This mutation in the conserved 
cytoskeleton-associated protein, glycine-rich (CAP-Gly) 
domain lowers the afﬁ  nity of p150
Glued for microtubules 
and EB1. Cell lines from patients are morphologically nor-
mal but show delayed recovery after nocodazole treat-
ment, consistent with a subtle disruption of dynein/dynactin 
function. The G59S mutation disrupts the folding of the 
CAP-Gly domain, resulting in aggregation of the p150
Glued 
protein both in vitro and in vivo, which is accompanied by 
an increase in cell death in a motor neuron cell line. Over-
expression of the chaperone Hsp70 inhibits aggregate 
formation and prevents cell death. These data support a 
model in which a point mutation in p150
Glued causes both 
loss of dynein/dynactin function and gain of toxic func-
tion, which together lead to motor neuron cell death.
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In humans, a G59S missense mutation has been iden-
tifi   ed in the gene encoding p150
Glued (DCTN1) in a kin-
dred with slowly progressive motor neuron disease (Puls et 
al., 2003). Affected patients develop adult-onset vocal fold 
 paralysis,  facial weakness, and distal-limb muscle weakness 
and atrophy. Clinical, electrophysiological, and pathologi-
cal investigations have confi  rmed the selective loss of motor 
neurons in this disorder (Puls et al., 2005). p150
Glued is the 
dynactin subunit   responsible for binding to dynein and micro-
tubules (Vaughan and Vallee, 1995; Waterman-Storer et al., 
1995). The G59S substitution occurs in the highly conserved 
NH2-terminal cytoskeleton-associated protein, glycine-rich 
(CAP-Gly) domain, which interacts directly with microtubules 
  (Waterman-Storer et al., 1995) and the microtubule plus-end 
protein EB1 (Ligon et al., 2003).
In this study, we examined the biochemical and cellular 
effects of the G59S substitution in p150
Glued. Our data sug-
gest that the G59S mutation leads to both decreased micro-
tubule binding and enhanced dynein and dynactin aggregation, 
suggesting that both loss of function and toxic gain of func-
tion contribute to the motor neuron degeneration observed in 
affected patients.
Results
The G59S mutation disrupts the binding 
of p150
Glued to microtubules and EB1
The G59S mutation is located within the highly conserved 
CAP-Gly domain of the p150
Glued polypeptide, a domain that 
  mediates the binding of dynactin to microtubules. We compared 
the microtubule binding affi  nities of wild-type and G59S p150
Glued 
peptides (Fig. 1 A). The CAP-Gly domain of wild-type p150
Glued, 
which spans residues 1–107, bound weakly to microtubules (un-
published data). This 1–107 peptide lacks the serine-rich region of 
p150
Glued (111–191), which may be required for effi  cient micro-
tubule binding by CAP-Gly proteins (Hoogenraad et al., 2000). In 
contrast, the binding of NH2-terminal residues 1–333 of the wild-
type protein to microtubules was robust, with a Kd of 1.1 ± 0.2 μM. 
The 1–333 fragment of p150
Glued carrying the G59S mutation bound
to microtubules with a Kd of 2.6 ± 0.5 μM, indicating a modest 
decrease in affi  nity. More striking, however, was the observation 
that even at saturating microtubule concentrations, only half of 
the mutant protein was able to bind to microtubules in this assay 
(Fig. 1 B). Similar results were observed in experiments with full-
length wild-type and G59S p150
Glued (unpublished data).
Figure 1. The G59S mutation impairs 
the binding  of  p150
Glued to microtubules. 
(A) Schematic representation of p150
Glued. 
Glycine 59 lies in the CAP-Gly microtubule 
binding   domain. The 1–107 fragment contains 
the CAP-Gly domain, and the 1–333 fragment 
contains the CAP-Gly domain, an adjacent ser-
ine-rich domain (residues 111–191), and a 
small part of the ﬁ  rst predicted coiled-coil do-
main. (B) Wild-type (WT) and G59S p150
Glued 
were expressed in vitro and incubated with 
  increasing concentrations of microtubules. 
The microtubule bound and unbound proteins 
were separated by centrifugation and visual-
ized by SDS-PAGE and ﬂ  uorography. The frac-
tion bound, as determined by densitometry, 
was plotted against the concentration of tubu-
lin ± SEM and ﬁ  tted to a rectangular hyper-
bola. (C) COS7 cells were transfected with 
GFP-tagged wild-type (top) or G59S (bottom) 
p150
Glued. Cells were ﬁ   xed after 48 h and 
stained for GFP (green) and microtubules (red). 
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We performed sequential microtubule binding experi-
ments, in which the unbound fraction of G59S p150
Glued 
(1–333) protein was incubated for a second time with a   satura-
ting concentration of microtubules (25 μM), and   observed 
that   60% of the protein pelleted with microtubules
(Fig. S1 A, available at http://www.jcb.org/cgi/  content/full/
jcb.200511068/DC1). These data suggest that there may be 
a rapid equilibrium between two populations of the mutant 
polypeptide, one that can bind and one that cannot.   Mixing 
of wild-type and G59S p150
Glued at a 1:1 ratio   resulted 
in 60% of protein pelleting with 25 μM microtubules (Fig. 
S1 B). These data suggest that mutant protein does not     
signifi   cantly inhibit the binding of wild-type polypeptide
to microtubules.
We next investigated the effects of the mutation on the 
binding of p150
Glued to microtubules in cells. We used transient 
transfection assays to compare the distribution of wild-type 
and G59S p150
Glued in COS7 cells as well as MN1 cells, motor 
neuron–like cells that extend neurites (Salazar-Grueso et al., 
1991; Brooks et al., 1998). Although endogenous dynactin 
generally has a punctate cellular localization, with decoration 
of dynamic microtubule plus ends, overexpression of p150
Glued 
results in the decoration of the microtubule cytoskeleton 
  (Waterman-Storer et al., 1995). As shown in Fig. 1 C, 24–48 h 
after transfection of GFP-tagged full-length constructs of 
wild-type p150
Glued, there was decoration of microtubules, as 
  assessed by colocalization with tubulin. In contrast, GFP-
tagged full-length G59S p150
Glued was distributed diffusely in 
the cytoplasm and showed no colocalization with tubulin (Fig. 
1 C). Similar results were obtained using GFP-tagged NH2-
  terminal 1–333 constructs of wild-type and G59S p150
Glued, 
as well as   untagged full-length wild-type and G59S p150
Glued 
constructs (unpublished data). We performed microtubule 
binding experiments using protein extract from COS7 cells 
that had been transfected with GFP-tagged, full-length 
p150
Glued. Almost all of the exogenous polypeptide from wild-
type p150
Glued–transfected cells pelleted with taxol-stabilized 
microtubules. However, only approximately half of the protein 
from G59S p150
Glued–transfected cells pelleted with microtu-
bules (unpublished data). This observation confi  rms our in 
  vitro data that only a portion of the G59S p150
Glued protein 
population may be available for microtubule binding.
The NH2-terminal CAP-Gly domain of p150
Glued binds 
to EB1 (Ligon et al., 2003). Crystallographic studies demon-
strate that the COOH terminus of EB1 contacts p150
Glued in 
a hydrophobic cleft of the CAP-Gly domain (Hayashi et al., 
2005). We therefore examined the binding of G59S p150
Glued 
to EB1 using affi  nity chromatography. The wild-type pep-
tide bound to the EB1 column and was retained until elution 
with high ionic strength buffer, but the G59S peptide had de-
creased retention on the column, indicating reduced affi  nity 
for EB1 (Fig. 2 A).
Figure 2.  The G59S mutation impairs the binding of p150
Glued to EB1 
and to microtubule plus ends. (A) Afﬁ   nity chromatography of in vitro–
translated wild-type (WT) or G59S p150
Glued (residues 1–333) over 
an EB1 column. Load (L), ﬂ  ow-through (F), wash (W), and eluate frac-
tions (E1 and E2) were analyzed by SDS-PAGE and Western blot us-
ing a polyclonal antibody to p150
Glued. There is less G59S p150
Glued 
in the eluate fractions, in comparison to wild-type p150
Glued, indicating 
a de-crease in G59S p150
Glued afﬁ  nity for EB1. (B and C) Live cell ﬂ  u-
ores-cence microscopy was used to observe the dynamics and localiza-
tion of p150
Glued in COS7 cells expressing low levels of GFP-tagged 
wild-type (B) and G59S (C) p150
Glued. Bar, 10 μm. B and C show still 
  images from Videos 1 and 2, respectively (available at http://www.jcb.
org/cgi/content/full/jcb.200511068/DC1).
Figure 3.  Expression of G59S p150
Glued does not alter the integrity of 
the dynactin complex. (A) Quantiﬁ  cation of levels of p150
Glued RNA in 
lymphoblast and ﬁ  broblast cell lines derived from patients carrying the 
G59S mutation and unaffected controls, as measured by RT-PCR. n = 3. 
(B) Western blot analysis of dynactin expression levels in ﬁ  broblast and 
lymphoblast cell lines from control individuals (C) and patients heterozy-
gous for the G59S mutation (P). Cell extracts were resolved by SDS-PAGE 
and probed for the dynactin subunit dynamitin, as well as DIC and actin. 
(C, right) An anti-p150
Glued monoclonal antibody (mAb) directed against 
the CAP-Gly domain does not recognize in vitro–translated (IVT) G59S 
p150
Glued. (left) An anti-p150
Glued polyclonal antibody (pAb) recognizes 
both the wild-type and mutant in vitro–translated protein. (D) Relative 
  levels of total and wild-type p150
Glued expressed in ﬁ  broblasts isolated 
from patients carrying the G59S mutation. (E) Protein extracts from G59S 
and control ﬁ  broblast cell lines were sedimented on 5–25% sucrose gra-
dients. The fractions were resolved by SDS-PAGE, and Western blot was 
performed using antibodies for the dynactin subunits p150
Glued and DIC. 
There is no peak of dynactin subunits in the lower density fractions, 
  indicating that these subunits are incorporated into the dynactin complex.JCB • VOLUME 172 • NUMBER 5 • 2006  736
Previous studies have shown that p150
Glued tracks dy-
namically with growing microtubule ends together with EB1 
(Vaughan et al., 1999). To investigate the effect of the G59S 
mutation on the localization of p150
Glued to microtubule plus 
ends, we transfected COS7 cells with GFP-labeled wild- type 
or G59S p150
Glued. We selected for cells with low levels of 
  expression, as microtubule plus-end tracking behavior is not 
evident at higher expression levels because of the decoration 
and bundling of microtubules induced by high levels of exog-
enous p150
Glued. Wild-type p150
Glued tracked dynamically with 
growing microtubule ends (Fig. 2 B and Video 1, available
at http://www.jcb.org/cgi/content/full/jcb.200511068/DC1), 
whereas the G59S construct showed no microtubule associa-
tion, even at tips (Fig. 2 C and Video 2). In cells with higher 
levels of   expression of the G59S construct, we noted apparent 
aggregates of misfolded protein, but these aggregates showed 
no   directed movement (Video 2).
The G59S mutation does 
not alter the structural integrity 
of the dynactin complex
To study the cellular effects of the G59S mutation in the 
p150
Glued subunit of dynactin, we established fibroblast and 
lymphoblast cell lines from two symptomatic individuals known 
to be heterozygous for the G59S missense allele. Control fi  bro-
blast cell lines were obtained from two age-matched control 
  individuals, and a control lymphoblast cell line was derived 
from an age-matched subject.
In these lines, we examined whether the G59S mutation 
alters the expression of dynein and dynactin. In both lympho-
blasts and fi  broblasts, quantitative RT-PCR analysis of RNA 
levels showed no difference in p150
Glued transcript levels be-
tween cell lines heterozygous for the G59S mutation and con-
trol cell lines (Fig. 3 A). Western blots of protein extract from 
patient cell lines showed up-regulation of levels p150
Glued, but 
not of dynein or other dynactin subunits, compared with 
control cell lines (Fig. 3, B and D).
To determine whether the wild-type and mutant proteins 
are both expressed in cells cultured from patients heterozygous 
for the G59S mutation, we performed quantitative Western blot-
ting using both a monoclonal antibody to the microtubule bind-
ing region of p150
Glued, which binds the wild-type protein with 
a much higher affi  nity than the mutant protein, and a polyclonal 
antibody to p150
Glued, which recognizes both forms equally well 
(Fig. 3 C). Analysis of patient cells indicated that the total level 
of p150
Glued expression (as determined using the polyclonal 
  antibody) is 147 ± 7% the level observed in control cells 
(Fig. 3 D). Western blots with the monoclonal antibody demon-
strated that patient cells express 82 ± 4% of the wild-type 
p150
Glued that control cells express (Fig. 3 D). Thus, we estimate 
that the mutant protein makes up  44% of the total p150
Glued 
population in patient cells.
To examine the structural integrity of the dynactin com-
plex, we fractionated cell extracts from the patient-derived 
and control fi  broblast cell lines by sucrose density gradient 
centrifugation. Intact dynactin was observed to sediment at 
 19S in both the patient and control samples, consistent 
with the large size of the multimeric complex. No signifi  cant 
pool of unincorporated p150
Glued subunits was observed in 
the lower S value fractions from either the patient or con-
trol cells (Fig. 3 E), suggesting that expression of the mutant 
polypeptide does not signifi  cantly disrupt dynactin structure 
and that the mutant polypeptide is incorporated into dynactin 
in these cells.
Figure 4.  Dynein, dynactin, and EB1 are localized normally in cells 
  heterozygous for the G59S mutation in p150
Glued. Control ﬁ  broblasts and 
ﬁ  broblasts from patients heterozygous for the G59S mutation were stained 
with antibodies to tubulin (MT; red) and dynamitin (A), DIC (B), EB1 (C), 
and the Golgi marker GM130 (D). We observed no difference in morphol-
ogy or microtubule organization in control and patient cells. There was a 
punctate, cytoplasmic localization of dynein and dynactin and microtubule 
tip localization of EB1 in both control and patient cells. The Golgi is intact 
and perinuclear in control and patient cells. Bar, 10 μm.MUTANT DYNACTIN CAUSES MOTOR NEURON DISEASE • LEVY ET AL.    737
The heterozygous G59S mutation 
in p150
Glued does not disrupt dynein/dynactin 
localization, Golgi morphology, microtubule 
organization, or spindle assembly
Incorporation of the mutant polypeptide into dynactin might 
be expected to disrupt dynactin localization in patient-derived 
cells; however, we observed no change in the cellular localization 
of dynactin in fi  broblasts derived from patients compared with 
control fi  broblasts (Fig. 4 A and Fig. S2 A, available at http://
www.jcb.org/cgi/content/full/jcb.200511068/DC1). Dynactin
was present diffusely in the cytoplasm in a fi  ne, punctate pattern, 
with no visible dynactin aggregates. We also noted no change 
in the cellular localization of cytoplasmic dynein, which was 
also found in a punctate cellular distribution, partially overlap-
ping with dynactin staining in both patient and control cells (Fig. 
4 B), or EB1, which was localized specifi  cally to microtubule 
tips (Fig. 4 C).
We examined the effects of the G59S mutation on the in-
tegrity of the Golgi and the assembly of the mitotic spindle in 
the patient-derived fi  broblasts. Disruption of dynactin by dyna-
mitin overexpression has been shown to disrupt the Golgi in in-
terphase cells (Burkhardt et al., 1997) and the mitotic spindle in 
dividing cells (Echeverri et al., 1996). However, no gross mor-
phological defects in the organization of the Golgi or the mitotic 
spindle were evident in patient-derived heterozygous cells un-
der normal growth conditions (Fig. 4 D and Fig. S2 B). In addi-
tion, no consistent defects in the growth rate were observed in 
the patient fi  broblasts (unpublished data).
The G59S mutation in p150
Glued impairs 
dynactin function
To test the patient fi  broblasts for dynactin function, we looked 
at several dynein/dynactin-dependent processes. Dynactin, as 
well as dynein and the dynein-interacting protein LIS1, are nec-
essary for directed fi  broblast migration (Dujardin et al., 2003). 
However, wounded monolayers of patient cells recovered at the 
same rate as control cells (unpublished data). Aggresome for-
mation has also been shown to be dynein dependent (Johnston 
et al., 2002). To test the effect of the mutation on aggresome 
formation, an androgen receptor containing an expanded poly-
glutamine repeat that induces inclusion formation (Merry et al., 
1998) was expressed in patient fi  broblasts. These fi  broblasts 
formed inclusions at a rate indistinguishable from control cells 
(unpublished data).
Although a single wild-type copy of the gene for p150
Glued 
may be suffi  cient to mediate dynein-dependent processes under 
normal conditions, conditions of cellular stress may reveal la-
tent effects of the G59S mutation. Nocodazole, a microtubule-
depolymerizing drug, causes dispersal of the Golgi. During 
recovery from nocodazole treatment, microtubules reas-
semble and the Golgi fragments coalesce near the centrosome 
in a dynein/dynactin-dependent manner (Corthesy-Theulaz 
et al., 1992). Hafezparast et al. (2003) have shown a slowing in 
the recovery of the Golgi after nocodazole treatment in fi  bro-
blasts cultured from homozygous Loa mice. Therefore, we 
  assayed the cytoskeletal and organelle recovery rates in hetero-
zygous G59S and control fi  broblasts after nocodazole washout. 
Microtubules were depolymerized and the Golgi body dispersed 
after 1 h of nocodazole treatment. 1 h after drug washout, mi-
crotubules had reassembled in both control and patient-derived 
cells; however, Golgi complex morphology was signifi  cantly 
different in patient cells. In control cells, 75 ± 2% of cells had 
an intact Golgi complex, 22 ± 3% of cells had a partially dis-
rupted Golgi complex, and 3 ± 1% of cells had completely dis-
rupted Golgi complex (Fig. 5, A and B). In contrast, in 
patient-derived cells only 46 ± 8% of cells had intact Golgi 
complexes, whereas 44 ± 5% of cells showed partial disruption 
and 11 ± 6% of cells showed complete disruption of the Golgi. 
Golgi reassembly after 24 h was essentially normal in patient-
derived fi  broblasts (unpublished data), indicating that expres-
sion of mutant dynactin slows but does not block the minus 
end–directed transport of Golgi elements toward the microtu-
bule organizing center.
We also observed that the localization of EB1 to micro-
tubule plus-end tips was altered in patient cells during no-
codazole recovery. After microtubule depolymerization with 
nocodazole, EB1 demonstrated diffuse cytoplasmic staining. 
After 30 min of recovery in conditioned growth media, EB1 
was localized specifi  cally to the plus ends of microtubules in 
control cells, forming comet tails that were 1.20 ± 0.06 μm 
long (Fig. 5 C). In patient-derived cells, EB1 was not limited to 
microtubule tips but was also observed to localize along micro-
tubules (Fig. 5 C). EB1 tail length increased signifi  cantly in pa-
tient-derived cells, often to >5 μm, although overlap of adjacent 
microtubules prevented exact measurements of the elongated 
EB1 tails. These data suggest a defect in the specifi  c localization 
of EB1 to microtubule plus ends.
To compare these data to a loss of function of dynactin, 
we used RNA interference to knockdown p150
Glued expression 
levels in HeLa cells by 70–90% (Fig. 5 E). This knockdown
caused dispersal of the Golgi throughout the cell body (Fig. 5 D). 
In addition, we observed an increase in the length of EB1 
comet tails from 1.08 ± 0.05 μm in mock-transfected cells to 
1.28 ± 0.07 μm in cells transfected with small interfering RNA 
(Fig. 5 F). The lengthening of EB1 comet tails is similar to what 
was observed in patient fi  broblasts recovering from nocodazole 
treatment and correlates with a loss of dynactin function.
The G59S mutation leads to aberrant 
aggregation of p150
Glued
In the microtubule binding assays described in Fig. 1, we ob-
served the binding of only half of the mutant p150
Glued polypep-
tide to microtubules, suggesting that some portion of the mutant 
protein population is unavailable for binding to microtubules. 
To  investigate this further, we expressed differentially tagged 
(T7 and His) truncated forms of wild-type and G59S p150
Glued 
in vitro and performed immunoprecipitation with an antibody to 
the T7 tag. Although our constructs, which include amino acids 
1–333, span part of the fi  rst coiled-coil domain of p150
Glued hypo-
thesized to mediate dimerization (Schroer, 2004), we observed 
no association of the T7- and His-tagged wild-type polypeptides 
(Fig. 6 A). However, we did observe coimmunoprecipitation of 
the differentially tagged NH2-terminal G59S constructs. These 
data suggest that the G59S polypeptide, but not the wild type, JCB • VOLUME 172 • NUMBER 5 • 2006  738
has a tendency to self- associate. There was no coimmuno-
precipitation after incubation of differentially tagged wild-type 
and G59S p150
Glued (unpublished data),   indicating that the wild-
type and G59S proteins do not   interact under these conditions. 
We next investigated whether aberrant biochemical spe-
cies of the G59S p150
Glued protein could be isolated from protein 
extracts of cells overexpressing this protein. COS7 cells were 
transfected with full-length wild-type or G59S GFP-tagged 
p150
Glued. 24 h after transfection, the extract from these cells 
was fractionated over a sucrose gradient and analyzed by SDS-
PAGE gel electrophoresis and Western blot. In cells transfected 
with wild-type p150
Glued, the peak concentration of dynamitin 
and endogenous p150
Glued was at 19S (Fig. 6 B). The exogenous 
p150
Glued protein (as determined by the increase in molecular 
weight that is due to the GFP tag) was present at 19S, as well 
as at less dense fractions. This indicates that some exogenous 
Figure 5. Cells heterozygous for the G59S mutation 
in p150
Glued have delayed recovery after microtubule 
  depolymerization.  Nocodazole washout experiments were 
performed on patient and control ﬁ   broblasts. Cells were 
treated with nocodazole for 1 h, washed twice with PBS, and 
returned to normal growth media. (A) After 1 h of recovery, 
cells were ﬁ  xed and stained for the cis-Golgi marker GM130 
(red) and microtubules (green). Control cells have compact 
and perinuclear Golgi, but patient cells have partially dis-
rupted Golgi at the same time point after drug washout. 
(B) Quantiﬁ  cation of Golgi morphology after 1 h of recovery, 
± SD (*, P < 0.05; **, P < 0.01). n = 3. (C) After 30 min of 
recovery, cells were ﬁ  xed and stained for EB1 (red) and micro-
tubules (green). Enlargements of merged images are shown 
at the bottom. Control cells show distinct tip localization of 
EB1, but patient cells show subtle mislocalization of EB1 
along microtubules. (D) HeLa-M cells, either mock-transfected 
or transfected with small interfering RNA against p150
Glued, 
stained with antibodies for EB1 or trans-Golgi marker 46. 
(E) Knockdown of p150
Glued, compared with cells transfected 
with a ﬂ   uorescein-labeled, nontargeting oligo or mock-
transfected cells. (F) Quantiﬁ  cation of the length of EB1 tails, 
± SD (*, P < 0.05). Bars, 10 μm. MUTANT DYNACTIN CAUSES MOTOR NEURON DISEASE • LEVY ET AL.    739
  protein is incorporated into the dynactin complex but some 
  remains unincorporated in lower molecular weight fractions, most 
likely because its expression is in excess of the other subunits 
of dynactin. In contrast, extracts from cells transfected with 
GFP-tagged G59S p150
Glued demonstrated higher molecular 
weight species in fractions 2–4. This suggests the presence of 
aggregated forms of G59S p150
Glued with a molecular weight 
well above that of endogenous dynactin (Fig. 6 B). Endogenous 
p150
Glued and dynamitin are not present in these fractions, indi-
cating that they do not copurify with the aggregated protein. The 
aggregated   protein remains soluble, as we did not observe the 
formation of detergent-insoluble aggregates (unpublished data).
Figure 6. G59S  p150
Glued aggregates in vitro and in vivo. (A) His- and T7-tagged constructs of wild-type and G59S p150
Glued were coexpressed in vitro. 
Immunoprecipitations were performed with anti-T7 antibody. The load (L), unbound (U), and immunoprecipitated (IP) fractions were resolved by SDS-PAGE 
and probed with antibodies to the His tag. The G59S construct, though not the wild type, runs as a doublet. We observed coimmunoprecipitation of the 
differentially tagged G59S constructs, indicating that the mutant protein self-associates. (B) Lysates from COS7 cells transfected with either GFP-tagged 
wild-type (WT) or G59S p150
Glued constructs were sedimented on 5–25% sucrose gradients. The fractions were resolved by SDS-PAGE and probed 
for the dynactin subunits p150
Glued and p50. The histogram indicates the mean percentage of protein in each fraction, as determined in three experiments, 
± SEM. G59S p150
Glued appears in the high-density fractions at a higher frequency than wild-type p150
Glued, which indicates it is incorporated into a 
high–molecular weight complex. n = 4. (C) COS7 cells transfected with GFP-tagged wild-type or G59S p150
Glued and ﬁ  xed after 96 h. Bar, 10 μm. 
(D) MN1 cells transfected with wild-type or G59S p150
Glued. Bar, 25 μm.JCB • VOLUME 172 • NUMBER 5 • 2006  740
As shown in Fig. 1 C, G59S p150
Glued was cytoplasmi-
cally dispersed in COS7 cells 24–48 h after transfection, 
whereas wild-type p150
Glued decorated microtubules. At longer 
time points, however, we noted a centripetal localization of 
the proteins. Wild-type p150
Glued became preferentially local-
ized along microtubules in the perinuclear region (Fig. 6 C). In 
contrast, G59S p150
Glued localized to inclusions surrounding the 
nucleus, which may correspond to the aggresomes of misfolded 
protein described by Johnston et al. (2002). These structures 
were also observed in very highly expressing cells at earlier 
time points, but their frequency increased with time after trans-
fection (Fig. S3, available at http://www.jcb.org/cgi/content/
full/jcb.200511068/DC1). In some MN1 cells transfected with 
GFP-tagged G59S p150
Glued, single or multiple inclusions were 
evident most often in the cell body (Fig. 6 D) and rarely in 
neurites. They were similar in appearance to those observed in 
motor neurons from the brainstem of an affected patient (Puls 
et  al., 2005), and their frequency increased with time after 
transfection (Fig. S3). Inclusions stained positive for dynein 
intermediate chain (DIC), the Golgi marker GM130, and the 
20S proteasome but not kinesin heavy chain, microtubules, neu-
rofi  laments, vimentin, microtubule-associated protein 2, Cu/Zn 
superoxide dismutase (SOD1), and survival of motor neurons, 
(unpublished data). Thus, in both neuronal and nonneuronal 
cells, mutation of the glycine 59 appears to decrease micro-
tubule binding by the p150
Glued CAP-Gly domain and leads to 
aggregation and inclusion formation by the mutant protein.
Inclusions of mutant protein are granular 
and associated with mitochondria
To look at the ultrastructure of the inclusions, transfected COS7 
cells and MN1 cells were observed by EM. MN1 cells trans-
fected with GFP-tagged full-length G59S p150
Glued and labeled 
with immunogold showed granular, nonfi  brillar inclusions of 
mutant protein (Fig. 7, A and B). Analysis of nonimmunogold-
labeled, glutaraldehyde-fi  xed COS7 cells demonstrated that the 
inclusions were not membrane bound (Fig. 7 C). These micro-
graphs show inclusions that look remarkably like the dynein- 
and dynactin-containing inclusions seen in patient neurons by 
immunohistochemistry (Puls et al., 2005).
In these ultrastructural studies, mitochondria frequently 
surrounded or were contained within the G59S p150
Glued inclu-
sions (Fig. 7 C). To examine the possibility that mitochondria 
localization was altered by the inclusions, COS7 cells were 
transfected with wild-type or G59S p150
Glued and stained with 
an antibody to mitochondrial chaperone Hsp60. Mitochondria 
Figure 7.  The p150
Glued inclusions are associated with 
  mitochondria.  (A and B) Low-magniﬁ   cation (A) and high-
magniﬁ  cation (B) electron micrographs of MN1 cells that have 
been transfected with GFP-labeled G59S p150
Glued and immuno  -
labeled with an antibody to GFP. Inclusions (i) and nuclei (n) 
are labeled. Bars, 500 nm. Inset, immunohis-tochemistry 
for DIC was performed on sections from the medulla of an 
affected patient. Bar, 10 μm. (C) High-magniﬁ  cation electron 
micrograph of a COS7 cell that has been transfected with GFP-
labeled G59S p150
Glued and ﬁ  xed with glutaraldahyde. No 
membrane surrounds the inclusion; the visible membrane is a 
nuclear envelope. Arrows indicate mitochondria surrounding 
and within G59S p150
Glued protein inclusions. Bar, 500 nm. 
(D and E) COS7 cells transfected with GFP-tagged wild-type 
(D) or G59S (E) p150
Glued and ﬁ  xed and stained using anti-
bodies for p150
Glued and Hsp60. Bar, 10 μm. (F) Quantiﬁ  ca-
tion of area of cells containing mitochondria in arbitrary units, 
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were partially relocalized in the area of the aggregates (Fig. 7, 
D and E). Quantifi  cation of the cross-sectional area of the cells 
that contained mitochondria demonstrated that mitochondria in 
cells transfected with G59S p150
Glued were less widely distrib-
uted than in cells transfected with wild-type protein (Fig. 7 F). 
It may be that mitochondria cannot be transported to the cell 
periphery because of aberrant interaction with the aggregated 
G59S p150
Glued. Alternatively, it is possible that loss of dynein/
dynactin transport causes mitochondrial mislocalization, as ex-
pression of dynamitin has also been shown to cause an inward 
collapse of the mitochondrial array (Varadi et al., 2004).
Expression of G59S p150
Glued induces 
death in neuronal cells
The expression of the G59S polypeptide led to an increase in 
cell death in MN1 cells, as determined by propidium iodide (PI) 
exclusion. Cells were transfected with GFP-tagged wild-type 
p150
Glued, G59S p150
Glued, or GFP alone. The MN1 cells trans-
fected with G59S p150
Glued demonstrated a signifi  cantly higher 
percentage of cell death than cells transfected with wild-type 
p150
Glued or GFP alone (Fig. 8 A). Furthermore, the percentage 
of cell death increased with time after transfection, correspond-
ing to an increase in the percentage of cells containing inclusions 
visible by immunofl  uorescence (Fig. S3). Embryonic rat motor 
neurons expressing G59S p150
Glued also demonstrated an in-
crease in cell death compared with motor neurons expressing ex-
ogenous wild-type p150
Glued in a time-dependent manner (Kalb, 
R.G., personal communication). Neuronal cells may be uniquely 
sensitive to the G59S polypeptide, as the expression of G59S 
p150
Glued does not increase cell death in COS7 cells (Fig. 8 A).
Overexpression of Hsp70 inhibits 
formation of G59S p150
Glued aggregates 
and prevents cell death
Overexpression of the chaperone Hsp70 has been reported to 
suppress protein aggregate formation and prevent cell death in 
several protein misfolding disease models (Barral et al., 2004). 
56 ± 6% of COS7 cells expressing the G59S p150
Glued protein 
for 2 d contained visible inclusions (Fig. 8, B and E). However, 
cells expressing both Hsp70 and G59S p150
Glued exhibited a dis-
perse localization of both exogenous proteins and only 17 ± 4% 
of transfected cells contained visible inclusions (Fig. 8, C and E).
Hsp70 containing the T13G mutation cannot undergo the con-
formational change necessary for chaperone activity (Sousa 
and McKay, 1998). In cells cotransfected with G59S p150
Glued 
and T13G Hsp70, the proportion of cells containing inclusions 
was not signifi  cantly different from that of cells transfected 
with G59S p150
Glued alone (Fig. 8, D and E). A Western blot 
of the cell protein lysates showed that levels of G59S p150
Glued 
were decreased when wild-type, but not T13G, Hsp70 was co-
expressed (Fig. 8 F). The chaperone function of Hsp70 may 
aid proper folding of G59S p150
Glued, thereby avoiding the for-
mation of inclusions and allowing effective degradation of the 
  mutant protein by the ubiquitin–proteasome pathway.
Transfection of G59S p150
Glued into MN1 cells led to 
an increase in cell death compared with cells transfected with 
wild-type p150
Glued (Fig. 8 A). However, coexpression of G59S 
p150
Glued and wild-type Hsp70 reduced the percentage of MN1 
cell death to levels similar to those of cells transfected with 
wild-type p150
Glued (Fig. 8 G). This protection was not observed 
when MN1 cells were cotransfected with G59S p150
Glued and 
either empty vector or T13G Hsp70  (Fig. 8 G). These data dem-
onstrate that expression of active Hsp70 reduces the amount of 
Figure 8.  Overexpression of Hsp70 decreases both aggregation of G59S 
p150
Glued and MN1 cell death. (A) Quantitation of cell death after transfec-
tion with wild-type (WT) or G59S p150
Glued or EGFP alone, as determined 
by PI exclusion. Values represent mean percentage of cell death in three 
sets of transfections, ± SEM (*, P < 0.05). n = 3. (B–D) Representative im-
ages of cells transfected with G59S p150
Glued alone (B), G59S p150
Glued 
and wild-type Hsp70 (C), or G59S p150
Glued and T13G Hsp70 (D). Cells 
were stained with antibodies for p150
Glued (green) and the hemagglutinin 
tag on the Hsp70 constructs (red). Bar, 10 μm. (E) Quantitation of the 
percentage of COS7 cells containing aggregates, ± SD (*, P < 0.05). 
n = 2. (F) Expression levels of p150
Glued and Hsp70 in lysates from cells 
that have been mock-transfected, transfected with G59S alone, and trans-
fected with wild-type or T13G Hsp70. Tubulin was used as a loading 
control. (G) Quantitation of mean percentage of cell death in MN1 cells 
48 h after transfection with wild-type and G59S p150
Glued and wild-type 
and T13G Hsp70 or empty vector, ± SEM (*, P < 0.05). Cotransfection 
of G59S p150
Glued and wild-type Hsp70 protects MN1 cells from death, 
but cotransfection of G59S p150
Glued with T13G Hsp70 or empty vector 
does not. n = 3.JCB • VOLUME 172 • NUMBER 5 • 2006  742
G59S p150
Glued aggregates, decreases the amount of p150
Glued 
expressed, and protects MN1 cells from the toxicity associated 
with expression of the mutant p150
Glued.
Discussion
A key question in the analysis of many neurodegenerative dis-
eases is the cell-type specifi  city observed: why would a mu-
tation in a ubiquitously expressed protein preferentially affect 
a single cell type? This question is particularly critical in the 
study of motor neuron diseases, such as Amyotrophic Lateral 
Sclerosis, in which multiple mutations in a ubiquitously ex-
pressed   protein, SOD1, result in motor neuron–  specifi  c degen-
eration and cell death. Several mechanisms have been proposed, 
including neuron-specifi   c aggregation and defects in axonal 
transport (for review see Bruijn et al., 2004).
We focus on the cellular effects of a point mutation in the 
p150
Glued subunit of dynactin. Dynactin is ubiquitously ex-
pressed in vertebrates, interacting with cytoplasmic dynein to 
serve as the major motor for microtubule minus end–directed 
transport in the cell. The dynein–dynactin complex is required 
for a range of   cellular functions, including mitotic spindle as-
sembly, ER-to-Golgi traffi  cking, and endosome and lysosome 
motility. Although complete loss of dynactin function is there-
fore likely to affect all cell types, patients expressing the G59S 
mutation in the p150
Glued   subunit of dynactin develop an auto-
somal-dominant, slowly progressive degeneration specifi  c to 
motor neurons (Puls et al., 2003).
The G59S missense mutation results in a subtle impair-
ment of dynactin function. A subtle loss of function in a protein 
required for retrograde axonal transport may be suffi  cient to in-
duce a slow degeneration of motor neurons. Mice with a tar-
geted disruption in dynactin function or with point mutations in 
cytoplasmic dynein heavy chain exhibit a slowly progressive 
loss of motor neurons, resulting in muscle atrophy (LaMonte 
et al., 2002; Hafezparast et al., 2003).
The G59S mutation also results in a toxic gain of function, 
as the G59S polypeptide is prone to aggregate. Parrini et al. 
(2005) have shown that evolutionarily conserved glycines in-
hibit aggregation because of their low propensity to form 
β structure. The G59S substitution alters a highly conserved 
glycine residue within the NH2-terminal CAP-Gly domain of 
the protein and is predicted to result in steric crowding and 
misfolding of this domain (Puls et al., 2003).
Comparisons of aggregate formation in both neuronal and 
nonneuronal cells overexpressing the G59S mutation suggest 
that motor neurons are uniquely vulnerable to aggregate forma-
tion, leading to enhanced cell death. One explanation for this 
observation is that motor neurons may not express adequate 
  levels of chaperones to cope with the high levels of misfolded 
protein. Recent studies have shown that motor neurons are not 
able to up-regulate Hsp70 in response to cellular stress and that 
they are particularly vulnerable to depletion of Hsp70 (Robinson 
et al., 2005). Consistent with this mechanism, overexpression of 
Hsp70 led to decreased aggregations of the G59S polypeptide 
and decreased cell death.
The mechanism by which aggregate formation leads to 
cell death remains to be determined. However, EM analysis of 
the aggregates demonstrates the presence of trapped organelles, 
including mitochondria. The aggregates may either actively trap 
organelles or passively disrupt microtubule-based transport via 
“organelle jams” (for review see Holzbaur, 2004). The seques-
tration of cytoplasmic dynein in these aggregates, as observed 
in both transfected cells and patient motor neurons (Puls et al., 
2005), would further disrupt axonal transport. This disruption in 
transport is likely to be most deleterious to motor neurons be-
cause of their overall size and extended axons.
Based on our observations, we propose the following 
model to explain the motor neuron–specifi  c phenotype observed 
in patients expressing the G59S mutation in dynactin (Fig. 9). 
The mutation leads to a decreased effi  ciency in minus end–
  directed transport. This subtle loss of function does not signifi  -
cantly perturb nonneuronal cells but may be suffi  cient to affect 
the overall effi  ciency of retrograde axonal transport in neurons. 
However, the mutation also results in a gain of function, as the 
G59S polypeptide has an enhanced propensity to misfold. 
  Aggregation of the misfolded protein is concentration depen-
dent, and the p150
Glued polypeptide is highly expressed in motor 
neurons (Melloni et al., 1995; unpublished data). Further, motor 
neurons may be specifi  cally vulnerable to misfolding and ag-
gregation of the G59S polypeptide because of insuffi  cient 
  expression of molecular chaperones. Finally, both the seques-
tration of active motors and the trapping of organelles by the 
p150
Glued aggregates will further exacerbate the inhibition of 
 axonal  transport.
Together, our data provide the foundation for a testable 
model for the cellular mechanisms leading to the motor 
neuron–specifi  c degeneration observed in patients expressing 
the G59S mutation, involving both loss of function and toxic 
gain of function. We anticipate that these studies will provide 
further insight into the mechanisms by which a mutation in an 
essential cellular protein can result in specifi  c degeneration of 
motor   neurons in vivo.
Figure 9.  Proposed mechanism of G59S p150
Glued–mediated motor 
neuron toxicity. G59S p150
Glued expression leads to motor neuron 
  toxicity through three intersecting pathways that lead to cell death. The 
mutation causes impaired microtubule and EB1 binding, which leads 
to disrupted dynein/dynactin-based transport. In addition, the muta-
tion causes misfolding of the CAP-Gly domain, which leads to aber-
rant self-association. The large proportion of unbound p150
Glued, along 
with the high expression levels of p150
Glued in neurons, leads to a high 
  cytosolic concentration of misfolded mutant protein resulting in aggre-
gates   speciﬁ  cally in neurons. This gain of function may induce further 
impairment in axonal transport, either by physical blockage of the axon 
or by sequestration of dynein and dynactin, leading to motor neuron–
  speciﬁ  c degeneration.MUTANT DYNACTIN CAUSES MOTOR NEURON DISEASE • LEVY ET AL.    743
Materials and methods
Microtubule binding
Wild-type and G59S p150
Glued were expressed and labeled with 
[
35S]methionine using the TNT T7 Quick system (Promega), clariﬁ  ed  by 
centrifugation at 39,000 g for 30 min, incubated for 30 min at 20°C with 
increasing concentrations of microtubules polymerized from puriﬁ  ed tubu-
lin (Cytoskeleton, Inc.), and stabilized with paclitaxel (Cytoskeleton, Inc.). 
Microtubule bound and unbound proteins were separated by centrifuga-
tion at 39,000 g for 20 min and analyzed by SDS-PAGE and ﬂ  uorography. 
Results were quantitated by densitometry using NIH ImageJ. Prism Soft-
ware (GraphPad) was used to ﬁ  t the binding data to the one-site ligand 
binding equation y = Bmax × x/(Kd + x).
Afﬁ  nity chromatography and Western blot
Afﬁ   nity matrices were prepared by cross-linking recombinant EB1 to 
  activated CH Sepharose 4B (GE Healthcare) beads at 4 mg/ml ligand. 
In vitro–expressed p150
Glued was incubated with the EB1-bound beads for 
30 min at room temperature. These mixtures were loaded onto a column 
and washed extensively with 50 mM Tris and 25 mM KCl, pH 7.4, 
with 0.1% Triton X-100. Retained proteins were eluted with 2 M NaCl. 
Fractions were analyzed by SDS-PAGE and Western blot.
Cell culture, transfections, immunocytochemistry, and nocodazole 
recovery assay
Fibroblast cell lines were derived from forearm punch skin biopsies from 
two symptomatic patients with the G59S mutation and from an age-
matched, unaffected control sibling (Priest, 1997). An additional age-
matched control ﬁ  broblast line (AG02222) was obtained from the Coriell 
Cell Repository. Lymphoblast cell lines were derived from blood samples 
from an affected family member carrying the G59S mutation using stan-
dard techniques. Cell lines were established in the Cytogenetics Labora-
tory at Georgetown University.
Fibroblast cell lines were maintained in Hams F-10 culture media 
supplemented with 15% fetal bovine serum; lymphoblast cells were 
maintained in RPMI media with 10% fetal bovine serum. COS7 cells 
(American Type Culture Collection) were maintained as described previ-
ously (Ligon et al., 2003). HeLa-M cells (a gift from A. Peden, Genen-
tech, South San Francisco, CA) were maintained in DME with 10% fetal 
bovine serum. For  immunoﬂ   uorescence assays, cells were grown to 
 75% conﬂ  uence and then ﬁ  xed in –20°C methanol and processed for 
immunocytochemistry. Monoclonal antibodies to tubulin (DM1A from 
Sigma-Aldrich), hemagglutinin (Sigma-Aldrich), kinesin heavy chain 
(Chemicon), neuroﬁ  lament (NE14 from Sigma-Aldrich), vimentin (Sigma-
Aldrich), microtubule-associated protein 2 (Sigma-Aldrich), Cu/Zn 
SOD1 (StressGen Biotechnologies), survival of motor neurons (BD Bio-
sciences), Golgi protein GM130 (BD Biosciences), cytoplasmic DIC 
(Chemicon), EB1 (BD Biosciences), TGN46 (Serotech), Hsp60 and -70 
(StressGen Biotechnologies), and dynactin subunits p150
Glued and dyna-
mitin (BD Biosciences) were purchased commercially. Afﬁ  nity-puriﬁ  ed 
polyclonal antibodies to p150
Glued, Arp1, and DIC have been described 
previously (Holleran et al., 1996; Tokito et al., 1996;   Ligon et al., 
2001). Immunostaining was visualized with Alexa 350–, 488–, and 
594–conjugated secondary antibodies (Invitrogen). Images were ac-
quired on a microscope (DMIRBE; Leica) with a 63× or 100× Plan Apo 
objective using OpenLab software (Improvision) and a charged-coupled 
device camera (Orca ER; Hamamatsu).
MN1 cells were maintained as described previously (Brooks et al., 
1998) and ﬁ  xed in 4% paraformaldehyde at room temperature for 10 min, 
permeabilized with 0.1% Triton X-100 in PBS for 10 min, and incubated 
with monoclonal antibodies to α-tubulin (clone 2.1 from Sigma-Aldrich) fol-
lowed by Texas red–conjugated secondary antibodies (Jackson Immuno-
Research Laboratories). Deconvoluted images were acquired with a 
microscope (Olympus) using DeltaVision software (Applied Precision) on a 
Silicon Graphics workstation.
Transient transfection assays were performed using Fugene (Roche) 
and plasmids encoding either wild-type or G59S full-length human 
p150
Glued or truncated constructs of the wild-type and G59S polypeptide 
spanning residues 1–333, both fused to GFP and untagged. Hemagglutinin-
tagged Hsp70 constructs were a gift from Y. Argon (University of Pennsyl-
vania, Philadelphia, PA).
For nocodazole recovery assays, patient and control ﬁ  broblasts 
were treated with nocodazole at 5 μg/ml for 1 h and then allowed to re-
cover for 0, 30, or 60 min or 24 h in conditioned culture media at 37°C 
in 5% CO2 before ﬁ  xation.
Microtubule plus-end dynamics assay
Live cell time-lapse recordings were performed on transiently transfected 
COS7 cells expressing either full-length wild-type or G59S p150
Glued or 
NH2-terminal residues 1–333 of wild-type or G59S p150
Glued, all fused to 
GFP. Cells on glass coverslips were sealed in an imaging chamber (FCS2; 
Bioptechs) and maintained at 37°C in culture media. Sequential time-lapse 
ﬂ  uorescent images were acquired at 12-s intervals.
RNA interference
HeLa-M cells were transfected using Oligofectamine (Invitrogen) with 
100 nM of a mixture of four RNA duplexes targeting different regions of 
human DCTNI (SMARTpool siRNA reagent [Dharmacon]; available from 
GenBank/EMBL/DDBJ under accession no. NM_004082): 5′-gaagauc-
gagagacaguu-3′, 5′-cgagcucacuacugacuua-3′, 5′-caugagcgcuccuug-
gauu-3′, and 5′-ggagcgcuguaucguaaga-3′. Cells were methanol ﬁ  xed 
after 72 h and processed for immunocytochemistry or resuspended in 
  denaturing sample buffer and processed for Western blot analysis.
RNA extraction and quantitative RT-PCR
RNA was extracted from cells using TRIzol (Invitrogen) and puriﬁ  ed 
with the RNAeasy clean-up kit according to the manufacturer’s protocol 
(QIAGEN), and cDNAs were generated using the High Capacity cDNA 
Achieve kit (Applied Biosystems). Quantitative PCR reactions were run in 
triplicate using the ABI Prism 7900 sequence detection system (Applied 
Biosystems). A forward primer (5′-gaagggcatggcatctttgtg-3′), a reverse 
primer (5′-gaagcagaagaatcaggtgtctct-3′), and a ﬂ  uorescent  probe 
(5′-FAM-ccagtcccagatccag-BHQ1-3′) were designed to amplify p150
Glued 
transcripts. Endogenous controls were simultaneously ampliﬁ  ed using com-
mercially available primers (Applied Biosystems). The reactions were per-
formed in triplicate and averaged, and p150
Glued Ct values (cycle number 
when signal reaches a threshold above background) were corrected for 
endogenous control Ct values using the ∆∆Ct method per the Applied 
Biosystems User Bulletin 2.
Sucrose density gradient centrifugation
Cells from 3–6 ﬂ  asks of patient ﬁ  broblasts and 3–6 ﬂ  asks of control ﬁ  bro-
blasts were washed in PBS, harvested, and homogenized in 20 mM Tris-
HCl, pH 7.4, 2 mM EGTA, and 1 mM EDTA with protease inhibitors 
(leupeptin, peptstatin A, N-p-tosyl-L-arginine methyl ester, and PMSF). Triton 
X-100 was added to 0.4%, and the homogenate was clariﬁ  ed by low-
speed centrifugation. The resulting supernatant fraction was layered over a 
5–25% linear sucrose density gradient and centrifuged at 126,000 g for 
16 h. The gradients were eluted in 0.5-ml fractions, which were resolved 
by SDS-PAGE, and analyzed by Western blot.
Aggregation assays
For aggregation assays, His- and T7-tagged constructs of wild-type and 
G59S p150
Glued were coexpressed in vitro and incubated for 2 h at 30°C. 
The reactions were then incubated sequentially with protein A beads to 
preclear the extracts, followed by protein A beads with bound monoclonal 
antibody to T7 (Novagen). After a 1-h incubation with antibody bound 
beads, the beads were isolated by centrifugation; washed four times with 
50 mM Tris, pH 7.3, 50 mM NaCl, and 0.1% Triton X-100; and eluted by 
boiling in denaturing gel sample buffer. The immunoprecipitates were ana-
lyzed by Western blots probed with antibodies to the His and T7 tags.
Cell death assays
A FACS-based survival assay was used to measure cell death (Taylor et al., 
2003). MN1 or COS7 cells were transfected with pEGFP wild-type and 
G59S p150 constructs in 6-well plates. Each transfection condition was 
performed in triplicate. After 24, 48, or 72 h, cells were harvested with 
trypsin, gently pelleted with centrifugation, and resuspended in 1 ml of 
PBS. Cells were stained with 2 μg/ml PI (Sigma-Aldrich) and gently 
vortexed. For each sample, 50,000 nongated events were acquired using 
a FACSCalibur instrument (BD Biosciences) and Cell Quest software (Becton 
Dickinson). GFP ﬂ  uorescence was collected in the FL-1 channel, and PI ﬂ  uo-
rescence was collected in the FL-3 channel in dot and density blot formats. 
Results were expressed as a percentage of PI-positive cells (cell death) 
divided by the total number of GFP-positive cells (transfected cells).
EM
MN1 and COS7 cells were plated on permanox chambered slides (Lab-
Tek; Nunc) and transfected with pEGFP wild-type and G59S p150 con-
structs or wild-type and G59S p150
Glued (untagged) constructs. 48 h 
after transfection, one set of cells (for immunogold labeling) was ﬁ  xed 
with 4% paraformaldehyde in PBS for 1 h and another set was ﬁ  xed in JCB • VOLUME 172 • NUMBER 5 • 2006  744
4% glutaraldehyde in cacodylate buffer. Paraformaldehyde-ﬁ  xed cells 
were washed three times with PBS and then blocked and permeabilized 
with 0.1% saponin for 1 h. The p150
Glued-GFP–transfected cells were 
then incubated with mouse polyclonal GFP antibody (Invitrogen), and 
p150
Glued-transfected cells were incubated in dynactin polyclonal anti-
body (UP235) followed by anti-mouse or anti-rabbit Nanogold (Nano-
probes). Slides were subjected to staining and silver enhancement as 
described previously (Tanner et al., 1996). After dehydration, embed-
ding, and sectioning, samples were examined with an electron micro-
scope (1200EX; JEOL).
Online supplemental material
Fig. S1 shows sequential and mixed microtubule binding of G59S 
p150
Glued. Fig. S2 shows that the localization of p150
Glued and the for-
mation of spindles are normal in cells heterozygous for the G59S muta-
tion in p150
Glued. Fig. S3 shows that the percentage of cells containing 
G59S p150
Glued inclusions increases with time after transfection. Video 1 
shows microtubule plus-end tracking of GFP-labeled wild-type p150
Glued 
in transfected COS7 cells. Video 2 demonstrates a loss of microtubule 
tip localization and plus-end tracking of GFP-labeled G59S p150
Glued 
in transfected COS7 cells. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200511068/DC1.
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